Ghana’s National Vaccine Institute (NVI) has been formally admitted to the Global Clinical Trials Forum (GCTF), a World Health Organisation–managed network established to strengthen clinical trial ecosystems in countries around the world.
The development marks a significant milestone for the NVI and positions Ghana as an active contributor to global health research governance.
Prof. Samuel Essien-Baidoo, Acting Director of Research and Development at the NVI, confirmed the admission, noting that membership confers access to extensive collaboration opportunities, knowledge-sharing platforms, and technical support from the WHO and fellow network members.
“There are no financial obligations. Ghana will benefit from the network of support for collaborations on clinical trials and capacity strengthening.”
Prof. Essien-Baidoo indicated that Ghana applied to join the forum on the recommendation of the WHO, following a successful stakeholder workshop.
About the Global Clinical Trials Forum
The GCTF was established following an agreement among member states at the World Health Assembly that clinical trial infrastructure worldwide requires stronger, more coordinated support. The forum operates under WHO governance and within a broader global framework for improving clinical trial standards. It functions not as an independent body, but as a WHO-led platform that convenes stakeholders to share knowledge, advocate for best practices, and drive coordinated action.
What Membership Means for Ghana
As a GCTF member, the NVI will be integrated into a global network comprising national health authorities, research institutes, regulatory bodies, healthcare providers, patient advocacy groups, and industry associations. The forum’s objectives include fostering collaboration between WHO and state actors, facilitating mutual learning and adoption of best practices, and promoting ethical, inclusive, and high-quality clinical trials.
The NVI’s responsibilities as a member include active participation in GCTF discussions and working groups, contributing public health and vaccine-focused leadership, aligning national policies with WHO norms and standards, and supporting knowledge dissemination at both national and regional levels. Ghana has indicated its intention to provide leadership in GCTF policy and technical discussions, with particular emphasis on the challenges and priorities of low- and middle-income country settings.
Global Context and Forum Operations
The GCTF is oriented towards making clinical trial approval processes more efficient while building enduring research capacity that becomes embedded in national healthcare systems. Members receive a quarterly newsletter documenting progress and participate in a comprehensive biennial review, during which members report on contributions made, identify areas for improvement, and map out the network’s path forward.
The Road Ahead
The NVI, led by Dr. Sodzi Sodzi-Tettey, has been advancing several strategic priorities concurrently, including a target to achieve local vaccine production by 2030, with a first locally manufactured vaccine expected by 2027. Admission to the GCTF complements these ambitions by providing access to technical tools, training materials, and collaborative partnerships that can enhance the quality, safety, and ethical integrity of clinical trials conducted within Ghana.
For the broader West African region, Ghana’s membership in the GCTF may serve as a model for other national health authorities and research institutions seeking to align their clinical trial ecosystems with WHO standards and gain access to global health research networks.
